Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Atrys Health SA ( (ES:ATRY) ) is now available.
Atrys Health, S.A. has filed its second semi-annual financial report for 2025, covering the period ended 31 December 2025, with the Spanish securities regulator in Madrid. The company states that the summarized annual accounts have been prepared under applicable accounting principles and provide a true and fair view of the group’s equity, financial position and results.
Management further notes that the interim management report offers a true and fair analysis of the required information for the consolidated group. Chief Executive Director María Antonia Isach Gabaldón has formally assumed responsibility for the information and signed off the semi-annual report on 27 March 2026, underscoring compliance with market disclosure and governance requirements.
The most recent analyst rating on (ES:ATRY) stock is a Buy with a EUR5.00 price target. To see the full list of analyst forecasts on Atrys Health SA stock, see the ES:ATRY Stock Forecast page.
More about Atrys Health SA
Atrys Health, S.A. is a Spain-based healthcare company headquartered in Madrid. The firm operates in the medical and health services sector, focusing on specialized clinical services and operating through a consolidated group of companies subject to Spanish financial market oversight.
Average Trading Volume: 50,193
Technical Sentiment Signal: Strong Sell
Current Market Cap: €223.4M
For an in-depth examination of ATRY stock, go to TipRanks’ Overview page.